OCUGEN, INC. Warrants Not Settleable in Cash, Fair Value Disclosure
OCUGEN, INC. (OCGN) had Warrants Not Settleable in Cash, Fair Value Disclosure of $8.40 million as of 2019-06-30, per its 10-Q filed 2019-08-09.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
us-gaap:WarrantsNotSettleableInCashFairValueDisclosure · last filed 2019-08-09
- 2019-06-30: Warrants Not Settleable in Cash, Fair Value Disclosure $8.40M.
- 2019-03-31: Warrants Not Settleable in Cash, Fair Value Disclosure $8.40M.
- 2018-12-31: Warrants Not Settleable in Cash, Fair Value Disclosure $8.40M.
- 2012-07-20: Warrants Not Settleable in Cash, Fair Value Disclosure $117.00K.
| Period end | Warrants Not Settleable in Cash, Fair Value Disclosure |
|---|---|
| 2019-06-30 | $8.40M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $8.40M 10-Q · filed 2019-05-15 |
| 2018-12-31 | $8.40M 10-K · filed 2019-03-22 |
| 2012-07-20 | $117.00K 10-Q · filed 2016-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |